Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats

The internalizing monoclonal antibody BR96 was conjugated to the anticancer drug doxorubicin (DOX) using an acid-labile hydrazone bond to DOX and a thioether bond to the monoclonal antibody. The resulting conjugate, termed BR96-DOX, binds to a tumor-associated Lewis(y) antigen that is abundantly exp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 1997-10, Vol.57 (20), p.4530-4536
Hauptverfasser:	SJÖGREN, H. O, ISAKSSON, M, WILLNER, D, HELLSTRÖM, I, HELLSTRÖM, K. E, TRAIL, P. A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adenocarcinoma - secondary Animals Antibodies, Monoclonal - therapeutic use Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Colonic Neoplasms - drug therapy Colonic Neoplasms - pathology Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Doxorubicin - therapeutic use Female Humans Immunotoxins - therapeutic use Liver Neoplasms - drug therapy Liver Neoplasms - pathology Liver Neoplasms - secondary Medical sciences Mice Mice, Nude Pharmacology. Drug treatments Rats Rats, Inbred BN Transplantation, Heterologous Transplantation, Isogeneic Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!